Alternative anti-influenza therapeutic strategies are urgently needed [1, 2] . One potential solution involves infusing pooled immunoglobulin from influenza-immune donors, termed influenza-specific hyperimmune immunoglobulin (Flu-IVIG) [3, 4] . There is some evidence from meta-analyses that passive transfer of antibody is a plausible therapy for severe influenza [5] . Recent placebo-controlled trials investigated convalescent plasma and hyperimmune IVIG during severe pandemic 2009 H1N1 (pH1N1) infection [3, 4] . Although reduced mortality and viral load was suggested, they lacked the design rigor to fully validate this approach.
Recently, a randomized, placebo-controlled INSIGHT FLU005 pilot study assessed Flu-IVIG for enhancing neutralizing antibodies in severe influenza infection [6] . Subjects infected with pH1N1 had greater hemagglutination inhibition (HAI) antibody titers against pH1N1 virus for approximately 3 days postinfusion with Flu-IVIG compared to the placebo controls [6] . While this indicates that Flu-IVIG could favorably modulate disease progression, a caveat concerns the utility of Flu-IVIG in future seasons. As Flu-IVIG is primarily manufactured in advance of future epidemics, there may be modest or no neutralizing activity against emerging strains.
HAI antibodies prevent viral attachment but usually target epitopes that accumulate point mutations and glycosylation, limiting specificity to small numbers of influenza strains [7] [8] [9] [10] . Antibodies with Fc-mediated functions commonly target conserved epitopes and have the capacity to mediate complement-directed killing [11, 12] , phagocytosis [13] and antibody-dependent cellular cytotoxicity (ADCC) toward influenza-infected cells [14] [15] [16] [17] . Fc gamma receptor (FcγR) IIIa is expressed on the surface of innate immune cells such as natural killer (NK) cells, and binds the Fc portion of antigen-bound immunoglobulin G (IgG) on influenza-infected cells. Upon cross-linking of Fc-engaged FcγRIIIa molecules, NK cells release cytokines, perforin, and granzyme from intracellular stores. ADCC enhances clearance of influenza-infected cells in vitro and protects from lethal H1N1 challenge in M A J O R A R T I C L E mice [18] [19] [20] [21] [22] . Furthermore, cross-reactive, ADCC-mediating antibodies commonly exist in the absence of neutralizing antibodies [18, 19, 23] .
Given the broad cross-reactivity and protective effects of ADCC antibodies, it is conceivable that ADCC antibodies may increase the effectiveness of Flu-IVIG toward drifted seasonal strains of influenza. We characterized Flu-IVIG for Fc effector functions and studied the effect of Flu-IVIG on ADCC responses in 24 subjects with influenza infection.
MATERIALS AND METHODS

Plasma Samples
Plasma was obtained from the INSIGHT FLU005 pilot study (INSIGHT 005: Flu-IVIG Pilot, ClinicalTrials.gov identifier NCT02008578) [6] . Of 31 subjects enrolled, 24 had polymerase chain reaction (PCR)-confirmed influenza A or B and 4 serial (preinfusion and days 1, 3, and 7 postinfusion) plasma samples available. Most subjects also had a 1-hour time point (21/24) and a day 28 time point (21/24) available. Subjects randomly received Flu-IVIG (0.25 g/kg; n = 13) or saline placebo (n = 11).
Intravenous Immunoglobulin
The Flu-IVIG studied was manufactured by Emergent BioSolutions under contract to the National Institutes of Health. The lot of Flu-IVIG used in the INSIGHT FLU005 pilot study was prepared in 2013 and had reciprocal geometric mean HAI antibody titers of 1:640 against the A/ California/7/2009(H1N1) pandemic influenza virus, 1:320 against the A/Victoria/361/2011(H3N2) influenza virus, and 1:160 against the B/Massachusetts/2/2012 influenza virus (see [6] for further details). We studied both the Flu-IVIG administered in the pilot study (prepared in 2013) and 3 additional, separately manufactured Flu-IVIG preparations (from 2014, 2015, and 2016, designated Flu-IVIG batches 1, 2, and 3 respectively) being used in an ongoing expanded clinical trial (INSIGHT FLU006, ClinicalTrials.gov identifier NCT02287467). Standard IVIGs manufactured in 2008 (prior to the 2009 pH1N1 pandemic), 2010, and 2016 were studied as comparators, with each containing pooled IgG from thousands of human immunodeficiency virus-negative donors. The IVIG prepared in 2016 is Intragam P (Seqirus Ltd) and we studied 3 additional batches of Intragam P (designated Intragam P batches 1-3). We also compared the Flu-IVIG from 2013, which was administered in the INSIGHT FLU005 pilot study, to a standard IVIG (Hizentra) also manufactured in 2013.
Recombinant Proteins and Influenza Virus
Recombinant influenza hemagglutinin (HA), nucleoprotein (NP), and simian immunodeficiency virus envelope proteins were purchased from Sinobiological. Neuraminidase (NA) protein, purified from whole inactivated influenza virus as previously described [19, 24] , was provided by Seqirus Ltd. A stabilized HA stem protein derived from A/California/07/2009(H1N1) was designed as previously described [25] , expressed using transient transfection of mammalian Expi293 cells (ThermoFisher) and purified using Ni sepharose Excel (GE Healthcare). The A/ California/07/2009 pandemic-like virus A/Auckland/01/2009 was used for infection of A549 cells.
FcγRIIa and FcγRIIIa Dimeric Binding Enzyme-Linked
Immunosorbent Assay
To compare the capacity of IVIG preparations and patient plasma to cross-link FcγRs, a dimeric recombinant soluble FcγR (rsFcγR) binding enzyme-linked immunosorbent assay (ELISA) was employed, as described previously [26] [27] [28] . In the patient plasma samples, Intragam P 2016 was used as a positive control for FcγR cross-linking and to normalize between ELISA plates as previously described [27] .
HA Stem IgG ELISA
One hundred nanograms of HA stem protein in phosphate-buffered saline was coated on 96-well plates overnight, blocked with 5% bovine serum albumin for 2 hours at 37°C, then washed. Serial 2-to 4-fold dilutions of antibody were incubated for 2 hours at room temperature and washed. Rabbit antihuman IgG horseradish peroxidase (1:4000 dilution, Aligent) was incubated at room temperature for 1 hour then washed. 3,3,5,5-tetramethylbenzidine (TMB) was added, color developed, stopped with 1 M hydrochloric acid (HCl), and absorbance read at 450 nm.
Antibody-Mediated NK Cell Activation
As a measure of NK cell activation, CD107a externalization was quantified by flow cytometry in response to antibodies immobilized by plate-bound influenza antigen, as previously described [18] . To model NK cell activation in influenza infection, NK-92-FcγRIIIa-green fluorescent protein (GFP) cell CD107a expression was measured when cultured with influenza virus-infected respiratory epithelial A549 cells, as previously described [29] .
ADCC of Influenza-Infected Cells
A lactate dehydrogenase (LDH) assay was adapted to assess ADCC-mediated killing of influenza-infected cells [30, 31] . 
Statistical Analysis
Analysis of covariance, with the baseline level as a covariate, was used to compare treatment differences at each time point. For titer data, analysis of covariance with the log-transformed preinfusion titer as a covariate was used to compare treatment groups for log-transformed titer levels at each follow-up time point. Treatment differences for log-transformed titer levels were back-transformed to obtain geometric mean titers (GMTs). FcγRIIIa titers reported as <40 and >2560 were imputed as 20 and 5120, respectively. Statistical analyses were performed using SAS version 9.4 software. Standard IVIG and Flu-IVIG preparations have been studied for treatment of severe influenza infections, but most analyses have been confined to neutralization assays [6, 32] . Antibodies with Fc-mediated effector functions commonly recognize a wide range of influenza strains and provide some protective immunity from influenza virus infection in vivo [21, 22, 33] . FcγRIIIa cross-linking antibodies in Flu-IVIG and 3 IVIG preparations from 2008, 2010 , and 2016 were first tested against recombinant hemagglutinin (rHA) protein from the A/California/07/2009(H1N1) pandemic swine influenza virus (pH1N1, Figure 1A ). There were 5-to 9-fold higher concentrations of anti-pH1N1 HA FcγRIIIa dimer binding antibodies in Flu-IVIG compared to standard IVIG made in 2010 or 2016 and a 66-fold higher concentration than IVIG made in 2008, prior to the 2009 pandemic ( Figure 1C) .
RESULTS
Flu
Anti-influenza FcγRIIa cross-linking antibodies mediating antibody-dependent phagocytosis (ADP) by alveolar macrophages has been highlighted as a possible mechanism of protection against heterologous influenza virus challenge in mice [33] . Flu-IVIG also demonstrated higher levels of FcγRIIa cross-linking antibodies to the pH1N1 rHA compared with standard IVIGs ( Figure 1B A B C D To assess breadth of responses, we tested FcγRIIIa dimer binding antibodies in Flu-IVIG against rHA proteins from 13 different influenza viruses ( Figure 1C ). Flu-IVIG contained higher concentrations of FcγRIIIa cross-linking antibodies against a variety of different rHA proteins by both effective concentration 50 (EC 50 ) ( Figure 1C Influenza-infected cells express a range of influenza proteins other than HA. NK cell activation assays were therefore performed using a respiratory epithelial cell line infected with pH1N1. Flu-IVIG contained more influenza-specific NK cell activating antibodies than IVIG preparations from 2008 and 2016 by EC 50 , but nearly identical EC 50 s were calculated for Flu-IVIG and an IVIG prepared in 2010 ( Figure 2B and 2D ). This suggests that influenza proteins besides HA may be involved in antibody-dependent NK cell activation and ADCC. We therefore tested the 4 IVIG preparations against 2 other known protein targets of influenza-specific ADCC (NA and NP), using the dimeric FcγRIIIa binding ELISA and the NK cell activation assay (Supplementary Figure 3 Figure 3B and 3D) .
ADCC assays were performed to assess killing of pH1N1-infected respiratory epithelial cells in the presence of Flu-IVIG or IVIG. Flu-IVIG demonstrated higher concentrations of ADCCmediating antibodies compared to IVIG ( Figure 2C and 2D) . Overall, Flu-IVIG contained higher levels of influenza-specific FcγR cross-linking, NK cell activating, and ADCC antibodies compared to standard IVIG in vitro, suggesting that this preparation will be useful for analyzing enhanced Fc-functional antibodies in subjects with influenza infections in vivo.
Flu-IVIG Contains HA Stem-Specific Antibodies
Monoclonal antibodies targeting the HA stem mediate potent ADCC in vitro [34] , and we therefore assessed HA stem antibodies. Flu-IVIG and the standard IVIG from 2010 demonstrated higher concentrations of pH1N1 HA stem-specific antibodies than IVIGs prepared in 2008 and 2016 by IgG ELISA, FcγRIIIa dimer ELISA, and NK cell activation assay ( Figure 3A-C) . The higher levels of HA stem antibodies in the 2010 IVIG presumably reflect recent infections with pH1N1 in the human population [35] .
Flu-IVIG Enhances FcγRIIIa Cross-Linking Antibodies Early After Infusion
Fc-functional antibodies are readily detectable in concentrated IVIG preparations [19] , but to provide clinical benefits these antibodies must be present after in vivo administration. We studied samples from 24 subjects from the INSIGHT FLU005 pilot study, first examining the 15 subjects enrolled that were naturally infected with pH1N1-like viruses. FcγRIIIa dimer ELISAs were performed with plasma from patients infused with either Flu-IVIG (8 patients) or placebo (7 patients). Plasma from recipients of Flu-IVIG demonstrated significantly more FcγRIIIa cross-linking antibodies against the pH1N1 rHA at 1 hour and 1 day postinfusion than placebo recipients, but not at 3 days, 7 days, and 28 days postinfusion ( Figure 4A and 4B) .
The rsFcγRIIIa dimer ELISA was also performed using plasma samples from all 24 patients with PCR-confirmed influenza infections: 15 patients infected with pH1N1, 3 patients infected with H3N2, and 6 patients infected with influenza B. As with the pH1N1-infected subjects alone, plasma samples from the Flu-IVIG group contained significantly higher titers of HA-specific FcγRIIIa cross-linking antibodies at 1 hour and 1 day postinfusion ( Figure 4C) , with Flu-IVIG/placebo ratios of 5.74 (95% confidence interval [CI], 3.52-9.35) and 3.77 (95% CI, 2.34-6.07), respectively. Collectively, these data suggest that Flu-IVIG infusion elevated HA-specific FcγRIIIa cross-linking antibody levels relative to the natural humoral immune response (placebo) early after infusion. We also assessed HA stem antibodies in the 15 patients with pH1N1-like infections. Flu-IVIG recipients had significantly higher HA stem-specific IgG at 1 hour and 1 day postinfusion than placebo subjects (Supplementary Figure 4) .
Flu-IVIG Increases Antibody-Dependent NK Cell Activation Early
Postinfusion ADCC-mediating antibodies are linked to less severe disease [29] . We determined whether plasma from Flu-IVIG-infused patients contains antibodies capable of stimulating NK cell degranulation. Flu-IVIG infused subjects with pH1N1 infections demonstrated greater HA-specific NK cell activating antibodies at 1 hour and 1 day postinfusion than placebo recipients ( Figure 5A ). The Flu-IVIG group also trended toward a higher GMT of NK cell activating antibodies against pH1N1-infected cells relative to the control group (P = .06; Figure 5B) , with a Flu-IVIG/placebo ratio of 2.48 (95% CI, .96-6.43). There was no significant difference between Flu-IVIG and placebo-infused patients beyond 1 day postinfusion ( Figure 5A and 5B).
Flu-IVIG Infusion Increases HA-Specific FcγRIIa Cross-Linking Antibodies
Above we showed that Flu-IVIG also contains FcγRIIa cross-linking antibodies, which may mediate ADP of influenza virions or infected cells ( Figure 1B and 1D) . FcγRIIa dimer ELISAs were therefore performed on plasma samples from the 15 pH1N1-infected subjects. At 1 hour and 1 day postinfusion, plasma samples from the Flu-IVIG infused patients demonstrated greater HA-specific FcγRIIa cross-linking than plasma samples from the control group ( Figure 6 ).
Flu-IVIG Infusion Enhances FcγRIIIa Cross-Linking Antibodies Against Diverse Influenza Virus HAs
We showed above ( Figures 1C, 1D , and 2D) that Flu-IVIG contains ADCC-mediating antibodies capable of binding to different strains and subtypes of influenza virus. The breadth of FcγRIIIa cross-linking antibodies was assessed in plasma samples from patients infected with pH1N1 viruses. As with the homologous H1 subtype, Flu-IVIG infusion increased rHA in 24 influenza-infected subjects (15 had pH1N1, 3 had H3N2, and 6 had B infection) are shown. As before, postinfusion GMTs were adjusted for preinfusion titers, which were 80 for the control group and 65 for the Flu-IVIG group. All plasma samples were also tested for dimeric rsFcγRIIIa binding antibodies against an irrelevant simian immunodeficiency virus type 1 glycoprotein 120, and background was subtracted for each plasma sample. Error bars represent standard error of the mean. ***P < .001. FcγRIIIa cross-linking antibodies against heterologous group 1 rHAs (H2 and H5 subtypes) at 1 hour and 1 day postinfusion ( Figure 7A ), although the responses were modest to H5. Humoral responses to group 1 rHAs started to emerge by day 3, suggesting rapid activation of cross-reactive memory B cells by infection. FcγRIIIa cross-linking antibodies against antigenically divergent group 2 HAs (H3 and H4 subtypes) were also higher in the Flu-IVIG group than the control group at 1 hour, 1 day, and 3 days postinfusion ( Figure 7B ). Modest antibody responses arose relatively late (between day 3 and day 7 postinfusion) in pH1N1-infected placebo recipients, consistent with a weakly cross-reactive humoral response to group 2 rHAs. 
DISCUSSION
There has long been interest in passively transferred antibodies to treat influenza, but in-depth laboratory analyses of randomized controlled trials are few. Treatment of severe human influenza with convalescent blood products significantly reduced mortality during the 1918 and 2009 pandemics [3] [4] [5] .
Commercially available IVIG preparations have also been studied for treatment of influenza [4, 36] but, unlike convalescent plasma, they are not enriched in influenza-specific antibodies. Flu-IVIG infusion increases serum HAI antibody titers in treated patients compared with placebo-infused controls [6] . However, because therapeutic Flu-IVIG is administered after influenza infection is established, Fc-mediated antibody functions may also be important for clearance of influenza-infected cells. IVIG preparations have been shown to contain broadly reactive antibodies with ADCC and ADP activity [19, 37] . A B Figure 5 . Enhanced influenza-specific antibody-mediated natural killer (NK) cell activation following influenza-specific hyperimmune immunoglobulin (Flu-IVIG) infusion. NK cell activation assays measuring CD107a expression were used to study serial plasma samples from 15 subjects with pandemic H1N1 (pH1N1) infections randomized to receive either Flu-IVIG or placebo. Mean changes from preinfusion or baseline for NK cell activating antibodies to pH1N1 recombinant hemagglutinin (rHA) protein (A) and geometric mean titers (GMTs) of NK cell activating antibodies to pH1N1-infected A549 cells (B) are shown. Data in A and B are adjusted for preinfusion antibody levels. All plasma samples were also tested for antibody-mediated NK cell activation against an irrelevant simian immunodeficiency virus type 1 glycoprotein 120, and background was subtracted for each individual sample. Error bars represent standard error of the mean. **P < .01, ***P < .001. [21, 22] . Furthermore, IVIG treatment reduced morbidity and mortality in ferrets following lethal influenza challenge with an H5N1 virus despite the absence of detectable HAI antibodies in the IVIG [36] . Flu-IVIG infusion resulted in increased Fc-functional antibodies from 1 hour to 1 day postinfusion, suggesting that Flu-IVIG treatment boosts ADCC and ADP activity for 1-2 days before the natural humoral response to infection catches up (at 3 days postinfusion). Analysis of FcγR cross-linking antibodies against influenza B in subjects infected with pH1N1 influenza A virus showed detectable responses for at least 1 week after Flu-IVIG infusion.
A small human influenza challenge study showed that high titers of ADCC-mediating antibodies were associated with reduced influenza virus shedding and less severe disease [29] . This INSIGHT FLU005 Flu-IVIG pilot study was not powered to assess whether the transient rise in Fc-functional antibodies modulated influenza disease severity or mortality and a larger study is currently under way (FLU006, ClinicalTrials.gov identifier NCT02287467). We speculate that the greatest benefit of Fc-functional antibodies in Flu-IVIG may be in subjects infected with antigenically drifted or novel influenza viruses to which Flu-IVIG does not contain neutralizing antibodies.
Fc-functional antibodies develop rapidly to influenza infection and by 3 days postinfusion, there was no significant difference between the Flu-IVIG and placebo groups. The rapid induction of HA-specific Fc-functional antibodies suggests recall of preexisting cross-reactive memory B-cells. Antigen recognition by these memory B cells stimulates differentiation into antibody-secreting plasma cells, which produce cross-reactive Fc-functional antibodies. Based on these results, it could be speculated that Flu-IVIG treatment may be more beneficial to influenza-naive patients, such as unvaccinated children, during influenza infection. Broadly binding Fc-functional antibodies capable of recognizing group 2 influenza A virus HAs (H3 and H4 subtypes) were also generated during the humoral immune response to pH1N1 virus infection in control subjects; however, this occurred at least 2 days later (after 3 days postinfusion) than production of Fc-functional antibodies against group 1 influenza virus HAs. The later induction of group 2 reactive Fc-functional antibodies could suggest activation of naive B cells that recognize HA epitopes conserved across group 1 and 2 influenza A viruses, such as the HA stem. Indeed, HA stem-specific antibodies were boosted early after Flu-IVIG infusion (1 hour and 1 day postinfusion) and increased in placebo-infused subjects by 3 days.
Previous work performed with plasma samples from the INSIGHT FLU005 pilot study showed that Flu-IVIG administration resulted in a spike in strain-specific HAI antibody titers from 1 hour to 3 days postinfusion, at least 3 days earlier than the HAI antibody response to natural infection [6] . In this study, we found that Flu-IVIG infusion caused an increase in HA-specific ADCC-mediating antibodies from 1 hour to 1 day postinfusion; this is 1-2 days earlier than the ADCC response to natural infection and approximately 2-4 days earlier than strain-specific HAI antibodies [6] . This is broadly consistent with our previous data on patients hospitalized with severe influenza due to either seasonal or avian H7N9 strains [31] . We speculate that the early presence of cross-reactive ADCC antibodies may be important for partial control of virus replication and spread until higher concentrations of strain-specific neutralizing antibodies are produced [40] .
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